Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2010 Dec;10(12):871-7. doi: 10.1038/nrc2933. Epub 2010 Nov 4.

Does tumour dormancy offer a therapeutic target?

Author information

1
Harvard Medical School, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Lawrence House, RH-302, Boston, Massachusetts 02114, USA.

Abstract

The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.

PMID:
21048784
DOI:
10.1038/nrc2933
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center